Ueshima, K.; Nishida, N.; Hagiwara, S.; Aoki, T.; Minami, T.; Chishina, H.; Takita, M.; Minami, Y.; Ida, H.; Takenaka, M.;
et al. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers 2019, 11, 952.
https://doi.org/10.3390/cancers11070952
AMA Style
Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M,
et al. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers. 2019; 11(7):952.
https://doi.org/10.3390/cancers11070952
Chicago/Turabian Style
Ueshima, Kazuomi, Naoshi Nishida, Satoru Hagiwara, Tomoko Aoki, Tomohiro Minami, Hirokazu Chishina, Masahiro Takita, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka,
and et al. 2019. "Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study" Cancers 11, no. 7: 952.
https://doi.org/10.3390/cancers11070952
APA Style
Ueshima, K., Nishida, N., Hagiwara, S., Aoki, T., Minami, T., Chishina, H., Takita, M., Minami, Y., Ida, H., Takenaka, M., Sakurai, T., Watanabe, T., Morita, M., Ogawa, C., Hiraoka, A., Johnson, P., & Kudo, M.
(2019). Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers, 11(7), 952.
https://doi.org/10.3390/cancers11070952